A Phase 3 interventional study of Maridebart cafraglutide and Placebo in Obstructive Sleep Apnea, sponsored by Amgen. Active, not recruiting at 57 sites in 11 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.
Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 70th largest by planned enrollment of the 594 interventional ones that give a count, is one of 33 that started in 2025, is one of 39 in phase 3, reaches primary completion later than 101 of the 159 other live ones, and was the 719th registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Nevada Dental Sleep · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–40 · Women only
Fisher and Paykel Healthcare · Sites in United States
Ages 22+
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
753 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 85 · Phase 3 45 · Phase 4 36
First in 1999; this study’s year is marked. 33 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 49 across the 594 interventional studies, 81 across the 157 observational. Of the 512 that completed or were terminated, 257 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
192 of 753 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
65 of the studies in Sleep Apnea, Obstructive with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT04814420Tulane UniversityAtrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study | 2026-11 |
| NCT07103941Isabel Moreno HayIOA Preventing Occlusal Changes With MAD Use | 2026-11-28 |
| NCT01857427Ulysses Magalang MDA Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities | 2026-12 |
Add all 65 to your calendar (.ics) → With an account.
Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive maridebart cafraglutide subcutaneously (SC).
Drug: Maridebart cafraglutide
Participants will receive placebo SC.
Drug: Placebo
Participants will receive maridebart cafraglutide SC.
Also known as: AMG 133, MariTide
Participants will receive placebo SC.
Change in Apnea-hypopnea Index (AHI) from baseline at Week 52
Time frame: At Week 52
Percent Change in AHI from baseline at Week 52
Time frame: At Week 52
Participants Achieving ≥ 50% AHI Reduction from baseline at Week 52
Time frame: At Week 52
Participants Achieving AHI < 5 or AHI 5 to 14 with Epworth Sleepiness Scale (ESS) ≤ 10 from baseline at Week 52
Time frame: At Week 52
Percent Change in Body Weight from baseline at Week 52
Time frame: At Week 52
Change in Sleep Apnea-specific Hypoxic Burden (SASHB) from baseline at Week 52
Time frame: At Week 52
Percent Change in High Sensitivity C-reactive Protein (hs-CRP) from baseline at Week 52
Time frame: At Week 52
Change in Systolic Blood Pressure (SBP) from baseline at Week 48
Time frame: At Week 48
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Sleep-related Impairment 8a Score from baseline at Week 52
Time frame: At Week 52
Change in AHI from Baseline at Week 24
Time frame: At Week 24
Percent Change in AHI from Baseline at Week 24
Time frame: At Week 24
Change in SASHB from Baseline at Week 24
Time frame: At Week 24
Change in ESS Score from Baseline at Week 52
Time frame: At Week 52
Change in PROMIS Short Form v1.0 Sleep-related Impairment 8b Score from Baseline at Week 52
Time frame: At Week 52
Change in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Domain and Summary Scores from Baseline at Week 52
Time frame: At Week 52
Change in Patient Global Impression of Severity (PGI-S) Sleep-Related Impairment, Sleep Quality, Sleepiness from Baseline at Week 52
Time frame: At Week 52
Percentage of Participants Achieving ≥10% Reduction in Body Weight from Baseline at Week 52
Time frame: At Week 52
Percentage of Participants Achieving ≥15% Reduction in Body Weight from Baseline at Week 52
Time frame: At Week 52
Percentage of Participants Achieving ≥20% Reduction in Body Weight from Baseline at Week 52
Time frame: At Week 52
Change in Waist Circumference From Baseline at Week 52
Time frame: At Week 52
Change in Waist-to-Height Ratio From Baseline at Week 52
Time frame: At Week 52
Change in Neck Circumference From Baseline at Week 52
Time frame: At Week 52
Percentage Change in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, Low-density Lipoprotein Cholesterol (LDL-C), and Triglycerides from Baseline at Week 52 in Fasting Conditions
Time frame: At Week 52
Percent Change in Fasting Insulin From Baseline at Week 52
Time frame: At Week 52
Change in Fasting Plasma Glucose (FPG) (mg/dL, mmol/L) From Baseline at Week 52
Time frame: At Week 52
Change in Hemoglobin A1c From Baseline at Week 52
Time frame: At Week 52
Change in Diastolic Blood Pressure (DBP) From Baseline at Week 48
Time frame: At Week 48
Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
Time frame: Up to Week 100
Plasma Concentration of Maridebart Cafraglutide at Week 52
Time frame: At Week 52
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Nov 2025 (actual). Primary completion is estimated for Aug 2027, 21 months after the start.
Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's planned 21 months is close to that.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Aug 2027, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide